{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:02:40Z","timestamp":1777420960907,"version":"3.51.4"},"reference-count":34,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T00:00:00Z","timestamp":1592956800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To review the efficacy and safety of the high-dose inactivated influenza vaccine quadrivalent (HD-IIV4) in the prevention of influenza in older adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>A literature search was performed using PubMed and Google Scholar with the search terms high-dose, influenza vaccine, and quadrivalent. Other resources included the Centers for Disease Control and Prevention (CDC), the prescribing information, and the manufacturer\u2019s website.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction:<\/jats:title>\n                    <jats:p>All relevant English-language articles of studies assessing the efficacy and safety of HD-IIV4 were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>HD-IIV4 is licensed by the Food and Drug Administration for the prevention of influenza in adults aged 65 years and older. The safety and immunogenicity of HD-IIV4 was demonstrated in a phase 3 trial, and the efficacy of the trivalent formulation (HD-IIV3) was demonstrated in a phase 3b-4 trial. HD-IIV4 carries a warning regarding the occurrence of Guillain-Barr\u00e9 syndrome. Adverse reactions, including injection-site pain and myalgia, were reported more frequently with HD-IIV4 than with HD-IIV3.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to Patient Care and Clinical Practice:<\/jats:title>\n                    <jats:p>Although the CDC recommends any age-appropriate influenza vaccine for adults aged 65 years and older, HD-IIV4 was associated with improved immunogenicity against the added B strain and HD-IIV3 provided better protection against influenza than the standard-dose vaccine. Other influenza vaccines have weaker evidence of efficacy in older adults. Therefore, HDIIV4 should be recommended as the vaccine of choice in adults aged 65 years and older.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>HD-IIV4 has proven immunogenic, safe, and effective in preventing influenza in older adults and should be recommended as the vaccine of choice in this patient population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1060028020935645","type":"journal-article","created":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T06:38:23Z","timestamp":1592980703000},"page":"89-97","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["High-Dose Inactivated Influenza Vaccine Quadrivalent for Older Adults"],"prefix":"10.1177","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1775-9497","authenticated-orcid":false,"given":"Elias B.","family":"Chahine","sequence":"first","affiliation":[{"name":"Lloyd L. Gregory School of Pharmacy, Palm Beach Atlantic University, West Palm Beach, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,6,24]]},"reference":[{"key":"bibr1-1060028020935645","unstructured":"Centers for Disease Control and Prevention. Disease burden of influenza. Accessed April 10, 2020. https:\/\/www.cdc.gov\/flu\/about\/burden\/index.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fflu%2Fabout%2Fdisease%2Fburden.htm"},{"key":"bibr2-1060028020935645","unstructured":"Centers for Disease Control and Prevention. People 65 years and older & influenza. Accessed April 10, 2020. https:\/\/www.cdc.gov\/flu\/highrisk\/65over.htm"},{"key":"bibr3-1060028020935645","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr6803a1"},{"key":"bibr4-1060028020935645","unstructured":"Office of Disease Prevention and Health Promotion. Immunization and infectious diseases. Accessed April 10, 2020. https:\/\/www.healthypeople.gov\/2020\/topics-objectives\/topic\/immunization-and-infectious-diseases\/objectives"},{"key":"bibr5-1060028020935645","unstructured":"Centers for Disease Control and Prevention. CDC seasonal flu vaccine effectiveness studies. Accessed April 10, 2020. https:\/\/www.cdc.gov\/flu\/vaccines-work\/effectiveness-studies.htm"},{"key":"bibr6-1060028020935645","unstructured":"Centers for Disease Control and Prevention. Immunogenicity, efficacy, and effectiveness of influenza vaccines. Accessed April 10, 2020. https:\/\/www.cdc.gov\/flu\/professionals\/acip\/immunogenicity.htm"},{"key":"bibr7-1060028020935645","doi-asserted-by":"publisher","DOI":"10.1186\/s12979-019-0164-9"},{"key":"bibr8-1060028020935645","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315727"},{"key":"bibr9-1060028020935645","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.07.059"},{"key":"bibr10-1060028020935645","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1608862"},{"key":"bibr11-1060028020935645","unstructured":"Fluzone\u00ae High-Dose Quadrivalent. Package insert. Sanofi Pasteur, Inc; 2019."},{"key":"bibr12-1060028020935645","unstructured":"Roguski K, Fry A. Travel-related infectious diseases\u2014influenza. In: Centers for Disease Control and Prevention Yellow Book 2020: Health Information for International Travel. Oxford University Press; 2017:chap 4. https:\/\/wwwnc.cdc.gov\/travel\/yellowbook\/2020\/travel-related-infectious-diseases\/influenza. Accessed April 10, 2020."},{"key":"bibr13-1060028020935645","first-page":"2143","volume-title":"Mandell, Douglas, and Bennett\u2019s Principles and Practice of Infectious Diseases","volume":"2020","author":"Treanor JJ","edition":"9"},{"key":"bibr14-1060028020935645","unstructured":"US Food and Drug Administration. 2020 Meeting materials, Vaccines and Related Biological Products Advisory Committee. Published March 4, 2020. Accessed April 10, 2020. https:\/\/www.fda.gov\/advisory-committees\/vaccines-and-related-biological-products-advisory-committee\/2020-meeting-materials-vaccines-and-related-biological-products-advisory-committee"},{"key":"bibr15-1060028020935645","doi-asserted-by":"publisher","DOI":"10.1128\/CDLI.3.5.507-510.1996"},{"key":"bibr16-1060028020935645","doi-asserted-by":"publisher","DOI":"10.1086\/599790"},{"key":"bibr17-1060028020935645","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1677437"},{"key":"bibr18-1060028020935645","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.08.016."},{"key":"bibr19-1060028020935645","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw641"},{"key":"bibr20-1060028020935645","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy088"},{"key":"bibr21-1060028020935645","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.09.050"},{"key":"bibr22-1060028020935645","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.01.063"},{"key":"bibr23-1060028020935645","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.09.105"},{"key":"bibr24-1060028020935645","unstructured":"Centers for Disease Control and Prevention. Vaccine information statement: influenza (flu) vaccine (inactivated or recombinant): what you need to know. Accessed April 15, 2020. https:\/\/www.cdc.gov\/vaccines\/hcp\/vis\/vis-statements\/flu.pdf"},{"key":"bibr25-1060028020935645","unstructured":"Department of Health and Human Services. Vaccine adverse event reporting system. Accessed April 10, 2020. https:\/\/vaers.hhs.gov\/"},{"key":"bibr26-1060028020935645","unstructured":"Sanofi Pasteur Inc. Fluzone high-dose quadrivalent. Accessed April 10, 2020. https:\/\/sanofiflu.com\/fluzone-high-dose-influenza-vaccine.html"},{"key":"bibr27-1060028020935645","unstructured":"Seqirus. Fluad quadrivalent. Accessed April 10, 2020. https:\/\/flu.seqirus.com\/FluadCategory\/Fluad\/p\/FluadPre?seasonCategoryCode=Seqirus_PreSeason"},{"key":"bibr28-1060028020935645","doi-asserted-by":"publisher","DOI":"10.1177\/1060028018772579"},{"key":"bibr29-1060028020935645","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6703a5"},{"key":"bibr30-1060028020935645","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6715a5"},{"key":"bibr31-1060028020935645","unstructured":"Red Book [online]. Fluzone high-dose 2019-20 formula. Accessed April 10, 2020."},{"key":"bibr32-1060028020935645","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2016.1215395"},{"key":"bibr33-1060028020935645","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.06.066"},{"key":"bibr34-1060028020935645","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2018.12.003"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028020935645","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1060028020935645","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028020935645","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:15:40Z","timestamp":1777374940000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1060028020935645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,24]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["10.1177\/1060028020935645"],"URL":"https:\/\/doi.org\/10.1177\/1060028020935645","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,24]]}}}